IRONDOSENCT06427343
The Effects of Low-Dose Versus High-Dose Intravenous IRON Therapy With Ferric DerisomaltOSE in Patients With Chronic Heart Failure and Iron Deficiency
At risk: Primary completion moved at least 10 months later.
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 4 versions: 3 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗
Notable Primary and study completion dates pushed to Aug 1, 2027 Show 4 more changesShow less
- Eligibility criteria shortened, about 6 words
- Primary endpoints: details revised at 1 of 1 entry
- Secondary endpoints: details revised at 5 of 13 entries
- Study description revised
Notable Primary endpoint revisedv2 Show 4 more changesShow less
- Eligibility criteria shortened, about 2 words
- Secondary endpoints revised (13)
- Study description revised
- Site contact updated
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Secondary (13)
Show 8 moreShow less
Arms and interventions
Participants randomized to this arm will receive repeat iron dosing as long as the serum ferritin was not \>700 ng/mL, or if TSAT was not \>40% during follow-up. Iron to be administered as ferric derisomaltose. Ferric derisomaltose will be administered according to the dosing schedule determined by the patient's body weight and hemoglobin value. Infused over a minimum of 15 mins for doses up to and including 1000mg, and a minimum of 30 mins for doses \>1000mg.
Participants randomized to this arm will receive repeat iron dosing if ferritin \<100 ng/mL or if ferritin 100-300 ng/mL and TSAT \<20% during follow-up. Iron to be administered as ferric derisomaltose in analogy to high-dose arm.
Drugs: High-dose ferric derisomaltose, Low-dose ferric derisomaltose
Sites
1 site in 1 country
- China-Japan Friendship HospitalBeijing, Beijing Municipality, China